| Abstract: | For some years direct gene tests have been available for many diseases and nearly every week new gene mutations are found and linked with diseases. By improving the diagnostic possibilities consequences for certain insurance branches will arise. Health and life insurance in particular will perhaps face radical chances, especially concerning the acceptance of contracts. If there is a contract between a policy holder and an insurance company, it is more important whether the cost-effectiveness of genetic screening is given. Exemplary this is calculated for a population-based screening for hemochromatosis. Furthermore it is relevant, whether the population will use available gene tests. The results of a pilot study will be presented. They show that there is a market for such products and that consequences for insurance companies are likely. |
